大肠炎相关的结直肠癌中的分子机制
Royce W Zhou1,2,3, Noam Harpaz4,5, Steven H Itzkowitz6,7,8
1The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Oncogenesis
|October 26, 2023
概括
结肠炎相关结肠直肠癌 (CAC) 中的慢性炎症驱动瘤的发展,与零星结肠直肠癌 (sCRC) 不同. 最近的研究使用先进的分析来了解炎症性肠病 (IBD) 中的CAC病原体.
科学领域:
- 胃肠道学和瘤学
- 分子生物学和遗传学
背景情况:
- 大肠的慢性炎症,如炎症性肠病 (IBD) 中所见,增加了结肠炎相关结肠直肠癌 (CAC) 的风险.
- CAC的遗传和分子途径与零星结直肠癌 (sCRC) 有相似之处,但在遗传变化的序列和时间上表现出明显的差异.
- 目前CAC发展的模型包括"现场癌症化"和"大爆炸"模型,但对CAC瘤发生的全面理解仍在发展中.
研究的目的:
- 审查了解结肠炎相关结肠直肠癌 (CAC) 病变的最新进展.
- 专注于遗传,表观遗传和环境因素,这些因素有助于过去五年中CAC的发展.
- 突出在IBD的背景下,对非发育不良组织进行公正,高分辨率的基因分析的发现.
主要方法:
- 对最近 (过去五年) 关于CAC病原学的科学文献的审查.
- 专注于使用无偏见,高分辨率的基因分析技术的研究.
- 分析与IBD患者的非失塑场癌症相关的发现.
主要成果:
- 最近的研究为CAC的遗传和表观遗传景观提供了新的见解.
- 高分辨率的剖析显示了IBD相关癌症的非失塑"场"中明显的突变特征和克隆扩张模式.
- 与遗传倾向相互作用的环境因素越来越被认为对CAC的开始和进展至关重要.
结论:
- 了解CAC的独特分子机制,特别是在IBD的背景下,对于开发向疗法至关重要.
- 炎症微环境的先进遗传分析为早期检测和化疗预防策略提供了新的途径.
- 需要进一步的研究,以充分阐明CAC和sCRC瘤发生之间的差异,并完善治疗方法.
相关概念视频
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
192
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
192
02:07Tumor Progression
6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K
01:30Inflammatory Bowel Disease II: Crohn's Disease
263
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
263
01:29Drugs for Treatment of Ulcerative Colitis in IBD
149
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
149